Meeting
2021 ASCO Annual Meeting
Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.
Authors
Maria Gonzalez-Cao
Instituto Oncológico Dr. Rosell, Barcelona, Spain
Maria Gonzalez-Cao , Clara Mayo de las Casas , Juana Oramas , Miguel-Angel Berciano-Guerrero , Luis De la Cruz , Pablo Cerezuela-Fuentes , Ana Maria Arance , Eva Muñoz-Couselo , Enrique Espinosa , Teresa Puértolas , Robert Diaz Beveridge , Sebastian Ochenduszko , Maria Jose Villanueva Silva , Laura Basterretxea , Lorena Bellido , Delvys Rodriguez-Abreu , Ana Drozdowskyj , Miguel Angel Molina Vila , Jose Antonio Lopez-Martin , Alfonso Berrocal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
2014-005277-36
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9528)
DOI
10.1200/JCO.2021.39.15_suppl.9528
Abstract #
9528
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).
First Author: Paola Queirolo
Poster
2017 ASCO Annual Meeting
A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
First Author: Jose A. Lopez-Martin
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2022 ASCO Annual Meeting
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.
First Author: Dirk Schadendorf